Supporting research into gynaecological cancers
Research supported by GRACE
GRACE is dedicated to research which will improve the treatment, recovery, and survival rates of women diagnosed in the future and are currently involved in several projects including investigation of chemotherapy resistant ovarian cancers.
Its findings feed into the wider UK cancer network, helping to influence and shape the diagnosis and treatment of these women. The charity is also keen to raise awareness of symptoms in order to promote early diagnosis.
In the last three years we have successfully established a specialist multi-disciplinary team across the Surrey, West Sussex and Hampshire Cancer Network for the treatment of the gynaecological cancers. The SWSH Cancer Network is based at St Luke’s Cancer Centre, Guildford and covers a population of 1.2 million people.
Almost all the research studies that we are, and will be, undertaking are collaborative and involve the clinicians from St Luke’s Cancer Centre at the Royal Surrey County Hospital and the scientists at the Postgraduate Medical School of the University of Surrey. In addition we have developed links with other centres and countries for collaborative research.
The ongoing research in our centre has two overlapping components: clinical and translational (laboratory based) research.
The clinical research is carried out alongside a very busy clinical practice. Our centre covers a large area with a population of approximately one million and is a centre for all gynaecological cancers treatment including surgery and oncology. We take part in a number of national and international studies and all patients are treated within a multidisciplinary context. We have close links with the University of Surrey and the research group in Postgraduate Medical School.
The translational research theme is new markers discovery in particular Engrailed (EN2) protein and the role of HOX genes in cancer. EN2 is a protein which is found in ovarian cancer and we are looking into its role and usefulness as a biomarker for cancer. We have now appointed a PhD and an MD student who are investigating EN2 and HOX genes in cancer.
If you would like more information regarding current clinical or translational research projects please contact: Dr A. Michael at the Royal Surrey Hospital.